Jesslyn Lu, MD
Endocrinology, Diabetes & Metabolism · Austin, TXNPI 1225363153
Payments from drug & device makers
Across 231 payments — averaging $25.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$840
- Medtronic$630
- Lilly USA, LLC$519
- Abbott$513
- Amgen$501
- Sanofi US Services Inc.$350
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$69512%
- Travel & lodging$2524%
- Food & beverage$4,92383%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $840 |
| Medtronic | 26 | $630 |
| Lilly USA, LLC | 28 | $519 |
| Abbott | 27 | $513 |
| Amgen(2 entities) | 25 | $501 |
| Sanofi US Services Inc. | 1 | $350 |
| Chiesi USA, Inc. | 3 | $326 |
| Cequr Corporation | 3 | $227 |
| Dexcom, Inc. | 8 | $211 |
| Sanofi-aventis U.S. LLC | 8 | $188 |
| BETA Bionics, Inc. | 6 | $184 |
| Insulet Corporation | 10 | $179 |
| Tandem Diabetes Care, Inc. | 7 | $161 |
| Bayer | 3 | $157 |
| Sequel Med Tech, LLC | 2 | $119 |
| Xeris Pharmaceuticals, Inc. | 5 | $97 |
| AbbVie | 5 | $90 |
| Rhythm Pharmaceuticals, Inc. | 3 | $76 |
| Ascendis Pharma Endocrinology Inc | 3 | $74 |
| Corcept Therapeutics | 4 | $70 |
| Kyowa Kirin, Inc. | 3 | $65 |
| Ascensia Diabetes Care US Inc. | 2 | $59 |
| Radius Health, Inc. | 2 | $49 |
| Boehringer Ingelheim | 2 | $46 |
| Recordati_rare_diseases_inc. | 2 | $42 |
| AstraZeneca | 2 | $38 |
| Novartis | 1 | $25 |
| Alvogen Inc | 1 | $20 |
| Amphastar Pharmaceuticals, Inc. | 1 | $20 |
| Mannkind Corporation | 1 | $18 |
| Sandoz | 1 | $17 |
| Tolmar, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Vistapharm, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$350
- MYCAPSSA$300
- MINIMED 780G$230
- MOUNJARO$125
- Kerendia$122
- CeQur Simplicity$118
How this compares
$5,950 in reported general payments places this provider in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 259 | $382,400 |
| MounjaroTirzepatide | 143 | $165,898 |
| JardianceEmpagliflozin | 119 | $160,897 |
| TrulicityDulaglutide | 76 | $132,423 |
| RybelsusSemaglutide | 45 | $69,392 |
| JanuviaSitagliptin Phosphate | 52 | $59,964 |
| FarxigaDapagliflozin Propanediol | 50 | $59,135 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $41,665 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $37,649 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $32,965 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $29,257 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $26,144 |
| TradjentaLinagliptin | 27 | $25,223 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $18,626 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $18,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $840 | $455,572320 claims |
| Lilly USA, LLCMounjaro, Trulicity | $519 | $298,321219 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $46 | $223,769176 claims |
| AstraZenecaFarxiga | $38 | $59,13550 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $188 | $41,66526 claims |
| AbbVieSynthroid | $90 | $7,82799 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Austin
- Thomas BlevinsAustin$7.4M
- Luis CasaubonAustin$3.5M
- Lindsay HarrisonAustin$2.2M
- Jean ChenAustin$1.8M
- Tira Chaicha-BromAustin$1.7M
- Valerie EspinosaAustin$1.2M
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.